Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Results of MajesTEC-3
OR
[magic_login_form]
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Studies / Trials Discussed
LBA6 – Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
Studies/trials discussed:
LBA6 – Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.